Table 2.
GSTT1 null and response to antineoplastic agents.
| Allele/genotype | Phenotype | Drugs | Population (study size, race/ethnicity) | PMID |
|---|---|---|---|---|
| GSTT1 null | decreased survival | cytarabine, mercaptopurine, prednisone and daunorubicin | Adult AML (n=193, Asian) | 11840286 [54] |
| GSTT1 null | decreased event free survival | Not specified | NHL/ follicular lymphoma subtype (n=89, unknown race) | 17454600 |
| GSTT1 null | decreased event free survival | cyclophosphamide, doxorubicin and fluorouracil | Breast neoplasms (n=152, Multiple) | 20459744 |
| GSTT1 null | decreased overall survival | paclitaxel or docetaxel and carboplatin or cisplatin | Ovarian cancer (n=118, Asian) | 19203783 |
| GSTT1 null | decreased overall survival, progression free survival | fluorouracil and platinum compounds | Gastric cancer (n=134, unknown race) | 19332728 |
| GSTT1 null | increased toxicity | cisplatin, cyclophosphamide, and vincristine | Pediatric Medulloblastoma (n=42, Multiple) | 18952980 |
| GSTT1 null | increased toxicity | rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone | de novo diffuse large B-cell lymphoma (n=94, Asian) | 20303013 |
| GSTT1 null | increased toxicity, increased overall survival | anthracylines | Hodgkin lymphoma (n=125, unknown) | 20977336 |
| GSTT1 null | increased survival | Not specified | NHL/ follicular lymphoma subtype (n=112, multiple) | 20029944 |
| GSTT1 null | increased overall survival | platinum compounds, doxorubicin and ifosfamide | Osteosarcoma (n=30, Multiple races) | 20577141 |
| GSTT1 null | increased event free survival, increased progression free survival | mitomycin | Bladder cancer (n=282, Asian) | 21045267 |
| GSTT1 null | increased overall survival | Not specified | Gastric cancer (n=130, Asian) | 21378360 |
| GSTT1 present | increased likelihood of complete response | homoharringtonine, cytarabine, daunorubicin | AML (n=254, Asian) | 18035413 |
| GSTT1 present | decreased survival | platinum compounds | Non-small cell lung cancer (n=973, White) | 20200426 |
| GSTT1 null | is not associated with toxicity (cardiac damage) | anthracylines | Pediatric ALL (n=76, White) | 19863340 |
| GSTT1 null | is not associated with toxicity | fluorouracil-based regimens (FOLFOX/FOLFIRI) | Colorectal neoplasms (n=346, unknown race) | 20385995 |
| GSTT1 null | is not associated with toxicity | platinum compounds | Mesothelioma (n=133, White) | 21765044 |
| GSTT1 null | is not associated with toxic death* | doxorubicin and cytosine arabinoside | AML (n=98, White) | 17671537 |
| GSTT1 null | Is not associated with survival | daunorubicin, cytosine arabinoside, mitoxantrone | AML (n=139, White) | 18207572 |
| GSTT1 null | Is not associated with survival | Not specified | Colorectal neoplasms (n=315, Multiple races) | 19748847 |
| GSTT1 null | Is not associated with survival | oxaliplatin | Colorectal neoplasms (n=65, Multiple races) | 20017670 |
| GSTT1 null | Is not associated with survival | paclitaxel/docetaxel, cisplatin | Gastric cancer (n=200, Asian) | 20331623 |
| GSTT1 null | Is not associated with survival | cisplatin-based regimens | Gastric cancer (n=138, unknown race) | 18443805 |
| GSTT1 null | Is not associated with survival | fluorouracil, oxaliplatin | Colorectal neoplasms (n=107, Multiple races) | 12072547 |
| GSTT1 null | Is not associated with survival | cisplatin, paclitaxel | Ovarian Cancer (n=24, unknown race) | 12851839 |
| GSTT1 null | Is not associated with treatment associated secondary neoplasms | etoposide/teniposide | treatment-related AML or myelodysplastic syndrome following pediatric ALL (n=302, Multiple races) | 10673738 |
| GSTT1 and GSTM1 double null | decreased survival | Not specified | Adult AML (n=106, unknown race) | 12351375 |
| GSTT1 and GSTM1 double null | increased likelihood of relapse | doxorubicin, vincristine, prednisone, cyclophosphamide, asparaginase, mercaptopurine, methotrexate, etoposide, cytarabine | Pediatric ALL (n=82, Asian) | 14607752 |
| GSTT1 and GSTM1 double null | decreased event free survival | Not specified | NHL/ follicular lymphoma subtype (n=89, unknown race) | 17454600 |
| GSTT1 and GSTM1 double null | decreased event free survival | rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone | de novo diffuse large B-cell lymphoma (n=60, Asian) | 20303013 |
*
the authors suggest that, with larger sample size, this association might be significant
Abbreviations: AML, acute myeloid leukemia; NHL, non-hodgkin lymphoma; ALL, precursor T-Cell lymphoblastic leukemia-lymphoma; FOLFOX, fluorouracil leucovorin and oxaliplatin; FOLFIRI, fluorouracil leucovorin and irinotecan.